Is Nuvectis Pharma Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: NVCT) stock is to Buy NVCT stock.
Out of 1 analyst, 0 (0%) are recommending NVCT as a Strong Buy, 1 (100%) are recommending NVCT as a Buy, 0 (0%) are recommending NVCT as a Hold, 0 (0%) are recommending NVCT as a Sell, and 0 (0%) are recommending NVCT as a Strong Sell.
What is NVCT's forecast return on equity (ROE) for 2023-2025?
(NASDAQ: NVCT) forecast ROE is -189.11%, which is considered weak.
What is NVCT's Price Target?
According to 1 Wall Street analyst that have issued a 1 year NVCT price target, the average NVCT price target is $21.00, with the highest NVCT stock price forecast at $21.00 and the lowest NVCT stock price forecast at $21.00.
The Wall Street analyst predicted that Nuvectis Pharma's share price could reach $21.00 by Mar 7, 2024. The average Nuvectis Pharma stock price prediction forecasts a potential upside of 17.85% from the current NVCT share price of $17.82.
What is NVCT's forecast return on assets (ROA) for 2023-2025?
(NASDAQ: NVCT) forecast ROA is -143.21%, which is lower than the forecast US Biotechnology industry average of 11.82%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.